CDISC and TransCelerate Announce New Standard for Breast Cancer
TransCelerate BioPharma Inc.(“TransCelerate”) is a non-profit organisation dedicated to improving the health of people around the world by accelerating and simplifying the research and development (R&D) of innovative new therapies.The Clinical Data Interchange Standards Consortium (CDISC) is a 501(c)(3) global non-profit charitable organisation that streamlines research and enables connections to healthcare through the development of clinical research data standards.
The need to rapidly and efficiently share new data within clinical research is one of the key initiatives within the world of clinical trial innovation and efficiencies. One of the major steps forward is the announcement CDISC and TransCelerate made earlier this year regarding the open availability of a new CDISC Therapeutic Area Standard for Breast Cancer.
“In order to optimize the care of any patient, we need to have a common set of information that is reliably collected on every one,” stated Dr. Laura Esserman, University of California San Francisco breast cancer surgeon and one of Time magazine’s top 100 most influential individuals in the world. “The CDISC standards will help us to ensure that we are all using a common language, which will then usher in an era where we can automate quality improvement, trial matching, seamless integration of data into trials, and streamline the process of improving the care, survival, and quality of life of our patients.”
For the full article please visit : http://www.prweb.com/releases/2016/05/prweb13423521.htm